Skip to content

Kidney Biomarkers of Acute Kidney Injury in Patients With Knee Arthroplasty

Kidney Biomarkers of Acute Kidney Injury in Patients With Knee Arthroplasty- a Pilot Study

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02642731
Acronym
dexpolvi
Enrollment
30
Registered
2015-12-30
Start date
2013-09-30
Completion date
2015-12-31
Last updated
2018-02-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Kidney Injury, Arthroplasty, Replacement, Knee

Keywords

total knee arthroplasty, Kidney function, Renal markers

Brief summary

Sensitive renal markers have been studied abundantly in connection with open heart, liver and transplantation surgery; however in major orthopaedic surgery their use is anecdotal. The aim of the present study is to evaluate use of sensitive renal markers, NGAL (Neutrophil gelatinase associated lipocalin ), KIM-1 (Kidney injury molecule- 1), LFABP (liver-type fatty acid-binding protein), and IL-18 (interleukin -18), in patients coming for elective TKA (total knee arthroplasty) as a pilot study before large study concerning acute kidney injury in orthopaedic surgery.

Detailed description

Acute renal deterioration is a serious adverse event in elective surgery. Serum creatinine based diagnostics of acute kidney injury may delay diagnosis and produce false negative results since serum creatinine is affected by diet, muscle mass, used hydration therapy. In recent times new markers have been developed and tested in order to find sensitive, fast and reliable marker of renal deterioration.

Interventions

None listed

Sponsors

Kuopio University Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
50 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* informed consent * allergy to NSAIDs

Exclusion criteria

* no informed consent

Design outcomes

Primary

MeasureTime frameDescription
Renal functiontime zero hours to 48 hoursS-creatinine, Cystatin C, estimated GFR

Secondary

MeasureTime frameDescription
Concentraton of sensitive renal markerstime zero hours to 24 hoursU-NGAL, P-NGAL, U-KIM-1, U-IL-18

Countries

Finland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026